Over the past twenty years, studies have shown that epithelial cancers grow in a specific environment characterized by tumor-induced changes ofthe infiltrating immune cells. This symbiotic relationship is critical for tumor growth and more importantly for tumor metastasis. Clearly a better understanding of these processes and the tumor types associated with each is critical to enhancing our understanding and treatment of malignant disease. During that same time period, it has been clear that the traditional approach to evaluate breast cancer using tumor histology does not adequately reflect the diversity of biology and the heterogeneity of this disease. As a result, new approaches to classifying breast cancer have been generated. The most commonly used, pioneered by this SPORE program, utilizes the expression of an intrinsic set of genes generated using cDNA microarray technology. Four different intrinsic subtypes were described-luminal A, HER-2-enriched, basal-like and normal-breast like. Interestingly, these different subtypes were associated with different clinical outcomes. Most recently, the Perou laboratory has identified a fifth subtype that is enriched in genes associated with tumor initiating cells and epithelial to mesenchymal transition. Patients with this subtype termed

Public Health Relevance

Breast cancer is the most common malignancy in women in the United States and the second leading cause of malignant death. We have found that a new subtype, claudin-low, are heavily infiltrated with immune cells, which are critical to the growth of these tumors. The current project seeks to understand how these immune cells regulate tumor growth and to target immune and tumor cells as a novel approach to therapy.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA058223-20
Application #
8547137
Study Section
Special Emphasis Panel (ZCA1-RPRB-0)
Project Start
Project End
Budget Start
2013-09-01
Budget End
2014-08-31
Support Year
20
Fiscal Year
2013
Total Cost
$163,589
Indirect Cost
Name
University of North Carolina Chapel Hill
Department
Type
DUNS #
608195277
City
Chapel Hill
State
NC
Country
United States
Zip Code
27599
Johnson, Gary L; Stuhlmiller, Timothy J; Angus, Steven P et al. (2014) Molecular pathways: adaptive kinome reprogramming in response to targeted inhibition of the BRAF-MEK-ERK pathway in cancer. Clin Cancer Res 20:2516-22
Chen, Christina T L; Liu, Ching-Ti; Chen, Gary K et al. (2014) Meta-analysis of loci associated with age at natural menopause in African-American women. Hum Mol Genet 23:3327-42
Phillips, Sarah; Prat, Aleix; Sedic, Maja et al. (2014) Cell-state transitions regulated by SLUG are critical for tissue regeneration and tumor initiation. Stem Cell Reports 2:633-47
Prat, A; Lluch, A; Albanell, J et al. (2014) Predicting response and survival in chemotherapy-treated triple-negative breast cancer. Br J Cancer 111:1532-41
Mango, Robert L; Wu, Qing Ping; West, Michelle et al. (2014) C-C chemokine receptor 5 on pulmonary mesenchymal cells promotes experimental metastasis via the induction of erythroid differentiation regulator 1. Mol Cancer Res 12:274-82
Palmer, Julie R; Viscidi, Emma; Troester, Melissa A et al. (2014) Parity, lactation, and breast cancer subtypes in African American women: results from the AMBER Consortium. J Natl Cancer Inst 106:
Tao, Jessica J; Castel, Pau; Radosevic-Robin, Nina et al. (2014) Antagonism of EGFR and HER3 enhances the response to inhibitors of the PI3K-Akt pathway in triple-negative breast cancer. Sci Signal 7:ra29
Mose, Lisle E; Wilkerson, Matthew D; Hayes, D Neil et al. (2014) ABRA: improved coding indel detection via assembly-based realignment. Bioinformatics 30:2813-5
Gatza, Michael L; Silva, Grace O; Parker, Joel S et al. (2014) An integrated genomics approach identifies drivers of proliferation in luminal-subtype human breast cancer. Nat Genet 46:1051-9
Allott, E H; Tse, C-K; Olshan, A F et al. (2014) Non-steroidal anti-inflammatory drug use, hormone receptor status, and breast cancer-specific mortality in the Carolina Breast Cancer Study. Breast Cancer Res Treat 147:415-21

Showing the most recent 10 out of 276 publications